Bioprocessing Technology Market Report 2026

Bioprocessing Technology Market Overview

• Bioprocessing Technology market size has reached to $71.39 billion in 2025 • Expected to grow to $139.77 billion in 2030 at a compound annual growth rate (CAGR) of 14.5% • Growth Driver: Escalating Incidences Of Chronic Diseases Fuel Growth In The Bioprocessing Technology Market • Market Trend: Bioprocessing Solutions Device To Maximize Their Profits In The Market • North America was the largest region in 2025.

What Is Covered Under Bioprocessing Technology Market?

Bioprocessing technology refers to the process that includes microbes, living cells, or elements of living organisms to synthesize biological products. It is commonly used to produce chemicals, food, flavor, fuel, and medications, with the aid of biocatalysts such as enzymes, and microbes. The main products of bioprocessing technology are biologics safety testing, cell culture, cell expansion, cell line development, flow cytometry, and tangential flow filtration. Biologics safety testing refers to the set of tests and procedures employed to evaluate the safety of biological products such as vaccines, blood products, gene therapies, and other biologics before the approval for human use. It is used to evaluate the purity, potency, identity, and stability of biological products. The bioprocess technology is applied in antibiotics, biosimilars, recombinant proteins, and others, that are used by biopharmaceutical companies, contract manufacturing organization, academic research institutes, food and feed industry, and contract research organization

What Is The Bioprocessing Technology Market Growth Forecast?

The bioprocessing technology market size is expected to see rapid growth in the next few years. It will grow to $139.77 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to increasing demand for biosimilars and recombinant proteins, rising adoption of automation in biomanufacturing, expansion of personalized medicine production, growing focus on process optimization, increasing outsourcing to CMOs. Major trends in the forecast period include increasing adoption of single-use bioprocessing systems, rising use of automated cell expansion platforms, growing integration of advanced biologics safety testing, expansion of continuous bioprocessing techniques, enhanced focus on scalable biomanufacturing.

What Is The Driver Of The Bioprocessing Technology Market?

The increased incidences of chronic diseases are expected to propel the growth of the bioprocessing technology market going forward. Chronic diseases are long-term health disorders that endure for at least a year and impair daily activities, require continuing medical care, or both. The bioprocessing technologies involves the discoveries of therapeutic proteins, polysaccharides, vaccines, and diagnostics essentials for the treatment of chronic diseases. Hence, the increased incidence of chronic diseases will support the growth of the bioprocessing technology market. For instance, in February 2024, according to the World Health Organization, a Switzerland-based agency of the United Nations, It is projected that over 35 million new cancer cases will arise by 2050, marking a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the increased incidences of chronic diseases will drive the growth of the bioprocessing technology industry.

Key Players In The Global Bioprocessing Technology Market

Major companies operating in the bioprocessing technology market report are Thermo Fisher Scientific Inc., Sartorius AG, Merck KGaA, Danaher Corporation, Lonza Group AG, GE Healthcare, Waters Corporation, STADA Arzneimittel AG, Bio-Rad Laboratories Inc., Applikon Biotechnology B.V., Agilent Technologies Inc., Solida Biotech GmbH, Fujifilm Healthcare Corporation, Catalent Inc., Asahi Kasei Medical Inc., Amgen Inc., Eppendorf AG, Repligen Corporation, Becton Dickinson and Company, MilliporeSigma, Novasep, Boehringer Ingelheim GmbH, Cytiva AB, Wuxi Biologics, AGC Biologics, Samsung Biologics, AbbVie Inc., Bristol Myers Squibb Company, Pfizer Inc., Roche Holding AG

Global Bioprocessing Technology Market Trends and Insights

Major companies operating in the bioprocessing technology market are focused on developing bioprocessing solutions, such as bioprocessing platforms, to address increasing demands for yield improvement, and maximize their profits in the market. A bioprocessing platform refers to a comprehensive system or set of technologies and methods designed for the efficient and large-scale processing of biological materials, to produce biopharmaceuticals or other bioproducts. For instance, in October 2023, WuXi Biologics, a China-based contract research, development, and manufacturing organization, launched WuXiUI, a high-productivity bioprocessing platform designed to enhance the productivity and quality of various mammalian cell lines and product modalities. WuXiUI utilizes an ultra-intensified intermittent-perfusion fed-batch (UI-IPFB) strategy, resulting in a 3 to 6-fold increase in productivity compared to conventional fed-batch processes. This platform addresses the growing demand for yield improvement, cost reduction, and environmental, social, and governance (ESG) considerations in bioprocess development.

What Are Latest Mergers And Acquisitions In The Bioprocessing Technology Market?

In August 2024, Merck KGaA, a Germany-based science and technology company, acquired Mirus Bio for $600 million. With this acquisition Merck KGaA aims to enhance its viral vector bioprocessing capabilities, enabling the company to provide integrated solutions across the entire manufacturing spectrum, from preclinical stages to commercial production. Mirus Bio is a US-based biotechnology company that specializes in providing innovative solutions for life sciences research and gene delivery applications.

What Defines the Bioprocessing Technology Market?

The bioprocess technology market includes revenues earned by entities through media preparation, biocatalyst optimization, mass production, downstream processing, and purification. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioprocess technology market also includes sales of process columns, dispersers or emulsifiers, screens or sieves, filters, fermenters or bioreactors, and process homogenizers which are used in bioprocess technology. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Bioprocessing Technology Market Report 2026?

The bioprocessing technology market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the bioprocessing technology industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.